Can Voriconazole Cause Peripheral Neuropathy?
Yes, voriconazole can cause peripheral neuropathy, though it is an uncommon adverse effect that typically occurs with prolonged therapy and is usually reversible upon drug discontinuation.
Direct Neurotoxicity of Voriconazole
Voriconazole-induced peripheral neuropathy is a recognized adverse effect, though the exact incidence varies by clinical context:
In acute invasive fungal infections: Peripheral neuropathy is rare but documented, with case reports demonstrating painful neuropathy developing during treatment 1, 2.
In chronic aspergillosis requiring long-term therapy: The incidence is substantially higher at approximately 9% among patients taking voriconazole for chronic conditions, with symptoms appearing after an average of 4 months of therapy 3.
Clinical presentation: Most cases manifest as numbness or tingling in the extremities (22 of 26 episodes), though some patients present with predominant leg weakness 3. The neuropathy is typically an axonal, length-dependent process 3.
Indirect Neuropathy Risk Through Drug Interactions
A critical and often overlooked mechanism is voriconazole's interaction with vinca alkaloid chemotherapy agents (vincristine, vinblastine), which dramatically increases neurotoxicity risk 4:
The combination of voriconazole with vincristine or other vinca alkaloids causes severe neurotoxicity including peripheral neuropathy and seizures 4.
Vinca alkaloids should generally NOT be coadministered with voriconazole; alternative antifungal therapy such as amphotericin B formulations or echinocandins should be used instead 4.
This interaction occurs because azoles increase vinca alkaloid levels through CYP3A4 inhibition, leading to enhanced neurotoxicity 4.
Prognosis and Reversibility
The majority of voriconazole-induced peripheral neuropathy cases are reversible:
Symptoms and signs typically disappear shortly after voriconazole discontinuation 1.
Most cases recover after the triazole medication is stopped 3.
However, approximately 9% of affected patients (2 of 22 in one series) experienced non-progressive but irreversible peripheral neuropathy 3.
Monitoring Recommendations
Patients on voriconazole therapy should be actively monitored for neurological symptoms, particularly those on long-term treatment 2, 3:
If peripheral neuropathy is suspected, diagnostic workup should include nerve conduction studies and exclusion of other causes of neuropathy 1, 3.
Consider dose reduction or cessation of therapy if neuropathy develops 3.
Therapeutic drug monitoring is essential, as neuropsychiatric toxicities (including neuropathy) are associated with supratherapeutic serum voriconazole levels 5.
Common Pitfalls to Avoid
Do not overlook drug-drug interactions: Always review concomitant medications, especially vinca alkaloids, before initiating voriconazole 4.
Do not assume all neuropathy is drug-related: In immunocompromised patients, exclude other causes including nutritional deficiencies, diabetes, HIV infection, and other medications 1.
Do not continue voriconazole without investigation: If neurological symptoms develop, perform nerve conduction studies and consider alternative antifungal agents 3.